科森科技：就出售子公司股权监管工作函发表独立意见

Core Viewpoint - Kosen Technology announced that it received a regulatory letter from the Shanghai Stock Exchange regarding the sale of its wholly-owned subsidiary Kosen Medical's equity, highlighting concerns over the company's ongoing losses while the subsidiary reported revenue and profit [1] Financial Performance - Kosen Medical achieved revenues of 366 million yuan and 354 million yuan for the first three quarters of 2024 and 2025, respectively [1] - The net profits for Kosen Medical were reported at 41.12 million yuan and 47.24 million yuan for the same periods [1] - In contrast, the parent company continues to incur losses during this timeframe [1] Regulatory Requirements - The exchange has requested the company to provide additional disclosures, including the reasons for the losses and the financial impact of the transaction [1] - An independent board member's interviews and document reviews found no evidence of related party transactions or undisclosed interests in the deal [1] Internal Transactions - A special audit covering the period from 2018 to September 30, 2025, confirmed that transactions between Kosen Medical and the parent company, as well as its subsidiaries, were necessary, reasonably priced, and had commercial substance [1]